Agilent Receives EU Approval for PD-L1 IHC 22C3 pharmDx
Agilent Technologies has announced European Union certification for its PD-L1 IHC 22C3 pharmDx as a companion diagnostic to identify patients with specific cancers who may be eligible for treatment with Merck’s KEYTRUDA® (pembrolizumab).
SANTA CLARA, Calif.–(BUSINESS WIRE)–Agilent Technologies Inc. (NYSE: A) today announced it has received European Union (EU) certification for PD-L1 IHC 22C3 pharmDx, Code SK006, as a companion diagnostic indicated to aid in identifying patients with epithelial ovarian, fallopian tube, or primary peritoneal carcinoma, whose tumors express PD-L1 and who may be eligible for treatment with KEYTRUDA® (pembrolizumab), Merck’s (known as MSD outside the United States and Canada) anti-PD-1 therapy. PD